· Lawyers suing over the opioid crisis may have overcome a major hurdle in their negotiations for a global settlement, announcing a proposed $26 billion settlement with three major pharmaceutical ...
 · In late 2015, Purdue paid $24 million in a settlement agreement to the state of Kentucky on the claim that Purdue had marketed their OxyCotin drug as safe. In 2017, Mallinckrodt PLC—a defendant in the County’s present lawsuit—paid $35 million to resolve an investigation into their monitoring and reporting methods for suspicious orders of opioids.
 · Now, as a new public-health crisis ravages states, Ohio’s Attorney General Mike DeWine filed a lawsuit Wednesday against a handful of pharmaceutical companies, including Purdue Pharma, Teva...
 · Attorney General Mike DeWine accused the companies of leading patients to believe that opioids were not addictive, which the lawsuit …
4 U.S. companies will pay $26 billion to settle claims over the opioid crisis The companies, including Johnson & Johnson and McKesson, will admit no wrongdoing. Billions of dollars in payouts will fund drug treatment and harm reduction programs.
The states' challenge added $1.2 billion to the original settlement. Overall, $97 million will go to Oregon and $183 million will go to Washington; all of that money will go toward addiction treatment and prevention in those states.
In 2020, Purdue Pharma reached a combined $8.4 billion criminal and civil settlement with the U.S. Department of Justice. The company accepted responsibility for its actions in the marketing of OxyContin, the pain medicine that became the poster drug of the opioid crisis.
U.S. pharmaceutical company Purdue Pharma, the maker of opioid painkiller OxyContin, has reached a new settlement with eight U.S. states and the District of Columbia to pay up to $6 billion in damages for the company's role in the U.S. opioid epidemic.
If approved, New Hampshire will receive approximately $46 million from the settlement. The result is an increase over the $27 million allocated to New Hampshire in Purdue's original bankruptcy plan—a plan objected to by Attorney General Formella.
Filed in the Ontario Superior Court of Justice, the class action suit alleges that Purdue was “negligent in the development, manufacture, distribution, marketing and sale of OxyContin and that the Defendants knew at all material times that anyone who ingest OxyContin would be at significant risk of becoming addicted to ...
The Sacklers will lose control of Purdue Pharma, which will be organized into a new company named Knoa Pharma with a board appointed by public officials. Company profits would go toward drug treatment programs.
In 2015, Sackler was deposed by four lawyers in Louisville, Kentucky. The deposition concerned the development and marketing of OxyContin under the watch of him and his family, who were and are active board members of their private company, Purdue Pharma.
Call: (844) 217-0912 (toll free) or (347) 859-8093 (international) Visit: PurduePharmaClaims.com. Write: Purdue Pharma Ballot Processing, c/o Prime Clerk LLC, One Grand Central Place, 60 East 42nd Street, Suite 1440, New York, NY 10165. Email: purduepharmainfo@primeclerk.com.
$6 billionMarch 3 (Reuters) - The Sackler family owners of Purdue Pharma LP reached a deal with a group of attorneys general to pay up to $6 billion in cash to resolve widespread litigation alleging that they fueled the U.S. opioid epidemic, bringing the OxyContin maker closer to exiting bankruptcy.
Sackler family members took out more than $10 billion from the company in the decade before it filed for bankruptcy, and they had a net worth of $14 billion in 2015, according to McMahon's decision.
In 2012, there were 793 million doses of opioids prescribed in the state, enough to supply every man, woman, and child, with 68 pills each.
In January, the city of Everett, Washington, filed a lawsuit against Purdue Pharma, the makers of OxyContin, alleging that the company knew the drug was being funneled into the black market but did nothing to stop it.
In 1998, the tobacco industry, 46 states, and six other jurisdictions entered into the largest civil-litigation settlement agreement in U.S. history. State attorneys general had sued tobacco companies, arguing that the companies should take up the burden of paying for the costs of treating smoking-related diseases.
Opioid Crisis: The lawsuits that could bankrupt manufacturers and distributors. The attorney behind a multibillion-dollar tobacco settlement in 1998 has turned his attention to the opioid epidemic. And he wants drug companies to pay. 2018 Dec 16.
The first targets are opioid manufacturers like Purdue Pharma, which makes oxycontin, the pill that fueled the opioid epidemic. Mike Moore: Purdue Pharma created an environment so that opioid use was okay. So if you prescribe your patients this drug, there's less than 1 percent chance they'll get addicted.
It's also simple why Moore is going after the biggest players in drug distribution: because they have much deeper pockets than the manufacturers. Purdue Pharma, for example, had less than $2 billion in revenue last year. Distributor McKesson, by contrast, had $208 billion in revenue.
Ohio's Republican attorney general Mike DeWine, who will be sworn in next month as governor, hired Mike Moore as soon as he decided to file suit against opioid manufacturers and distributors. Attorney General Mike DeWine: They flooded the State of Ohio with these opioid pills that they knew would kill people.
Purdue Pharma declined our request for an interview, but said in a statement that when the FDA approved oxycontin in 1995 it authorized the company to state on the label that "addiction to opioids legitimately used is very rare.".
As Mississippi's attorney general, he engineered the historic 1998 settlement under which Big Tobacco paid billions to address smoking-related health issues. In 2015, he convinced BP to settle multibillion-dollar lawsuits over its huge oil spill in the Gulf of Mexico.
Attorneys general from four states – North Carolina, Tennessee, Pennsylvania and Texas – lauded Monday’s settlement as “an important step” in combating the opioid epidemic.
The sudden settlement Monday followed marathon negotiations that went nowhere last week.
The agreement still requires the approval of more than 40 states and hundreds of cities and counties. Three major drug distributors and the pharmaceutical giant Johnson & Johnson have agreed to a $26 billion settlement with states to resolve thousands of lawsuits over the country's opioid crisis, officials announced Wednesday.
Three major drug distributors and the pharmaceutical giant Johnson & Johnson have agreed to a $26 billion settlement with states to resolve thousands of lawsuits over the country's opioid crisis, officials announced Wednesday.
The pharmaceutical companies that fueled the opioid crisis must be held legally accountable. But to confront the social problems at the root of the addiction crisis, we’ll need political victories, not just courtroom ones.
An estimated five hundred thousand people have died of opiate overdoses in the United States since 1999. The role of corporate actors in causing and prolonging that public-health crisis has been well understood since at least 2007. Predictably, then, this is not the first attempt to hold drug companies accountable in civil court.
A master settlement agreement through which hundreds of government plaintiffs withdraw their individual lawsuits and submit to a national disbursement framework is an unusual outcome for civil litigation. But it is not entirely unprecedented.
Four years ago, after my Pennsylvania hometown experienced more than fifty opiate overdoses in forty-eight hours, I wrote that the most dangerous response to the opioid crisis was one that rejected collective political action.